Open platform Biotech Dental recently launched LaGalaxy, a comprehensive software platform for clinical and administrative tasks, presenting a potential cross-sell with hardware offerings and an opportunity to bundle software licenses with implants, scanners, and other equipment.

Acquisition synergies The company was acquired by Henry Schein in 2023, indicating strong distribution channels and potential collaboration with Schein’s extensive customer base for expanded product reach and bundled solutions.

3D intraoral focus Recent partnerships aim to develop highly accurate 3D intraoral scanners, suggesting a sales opportunity to position Biotech Dental scanners alongside existing implants and software, appealing to practices investing in digital dentistry.

R&D leadership With over 10 percent of turnover invested in R&D and a history of innovation, there is a readiness to adopt and co-develop new technologies; this can facilitate pilot programs, betas, or exclusive product collaborations with target clinics.

Global clinical impact Having sold over two million implants and serving dental surgeons worldwide, Biotech Dental demonstrates scale and credibility, making it a strong candidate for expanded product lines, service contracts, and premium support offerings to high-volume practices.